Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538 (nivolumab) in advanced NSCLC
NCT02175017Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2014
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02175017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175017.